Home / News / Event #1064132 SEC EDGAR published this disclosure on 2026-08-31. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗ accession 0001829126-26-009543
acquired disposed A
code P
direct or indirect D
form 4
is derivative false
issuer name Veraxa Biotech AG - Post de-SPAC
label Open market purchase
Source record & verification Dates, provenance and technical details
Context links are based on the recorded entity type Recorded payload Structured source data
Recorded payload JSON payload as stored after parsing {
"accession": "0001829126-26-009543",
"acquired_disposed": "A",
"code": "P",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "Veraxa Biotech AG - Post de-SPAC",
"label": "Open market purchase",
"person_name": "Antz Christoph Rudiger",
"price": 1.53,
"role": "Director, Chief Executive Officer",
"security": "Ordinary Shares",
"shares": 5000,
"shares_owned_after": 5000,
"source_path": "edgar/data/2123284/0001829126-26-009543.txt",
"ticker": "VRXA",
"transaction_date": "2026-08-27",
"value": 7650
}
Evidence-based analysis facts, provenance and explicit model coverage Descriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.